Trade Petros Pharmaceuticals, Inc. - PTPI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 1.93 |
| Open* | 1.75 |
| 1-Year Change* | 257.14% |
| Day's Range* | 1.54 - 1.9 |
| 52 wk Range | 0.37-5.20 |
| Average Volume (10 days) | 76.89K |
| Average Volume (3 months) | 2.81M |
| Market Cap | 8.83M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 20.71M |
| Revenue | 4.33M |
| EPS | -1.51 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 2, 2023 | 1.93 | 0.34 | 21.38% | 1.59 | 2.01 | 1.59 |
| Sep 29, 2023 | 1.63 | 0.19 | 13.19% | 1.44 | 1.63 | 1.43 |
| Sep 28, 2023 | 1.42 | -0.07 | -4.70% | 1.49 | 1.55 | 1.42 |
| Sep 27, 2023 | 1.46 | -0.05 | -3.31% | 1.51 | 1.54 | 1.42 |
| Sep 26, 2023 | 1.48 | -0.10 | -6.33% | 1.58 | 1.59 | 1.48 |
| Sep 25, 2023 | 1.53 | -0.03 | -1.92% | 1.56 | 1.58 | 1.52 |
| Sep 22, 2023 | 1.49 | 0.01 | 0.68% | 1.48 | 1.55 | 1.48 |
| Sep 21, 2023 | 1.51 | 0.00 | 0.00% | 1.51 | 1.51 | 1.51 |
| Sep 20, 2023 | 1.49 | -0.09 | -5.70% | 1.58 | 1.58 | 1.48 |
| Sep 19, 2023 | 1.52 | -0.09 | -5.59% | 1.61 | 1.61 | 1.52 |
| Sep 18, 2023 | 1.70 | -0.08 | -4.49% | 1.78 | 1.78 | 1.69 |
| Sep 15, 2023 | 1.72 | -0.04 | -2.27% | 1.76 | 1.77 | 1.59 |
| Sep 14, 2023 | 1.80 | -0.07 | -3.74% | 1.87 | 1.88 | 1.74 |
| Sep 13, 2023 | 1.84 | -0.09 | -4.66% | 1.93 | 1.98 | 1.79 |
| Sep 12, 2023 | 1.93 | 0.03 | 1.58% | 1.90 | 1.96 | 1.79 |
| Sep 11, 2023 | 1.86 | 0.03 | 1.64% | 1.83 | 1.87 | 1.83 |
| Sep 8, 2023 | 1.75 | -0.66 | -27.39% | 2.41 | 2.41 | 1.73 |
| Sep 7, 2023 | 2.33 | -0.06 | -2.51% | 2.39 | 2.39 | 2.32 |
| Sep 6, 2023 | 2.30 | 0.02 | 0.88% | 2.28 | 2.36 | 2.28 |
| Sep 5, 2023 | 2.34 | -0.07 | -2.90% | 2.41 | 2.42 | 2.28 |
Petros Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total revenue | 7.81126 | 9.55947 | 15.5772 | 14.0512 |
| Revenue | 7.81126 | 9.55947 | 15.5772 | 14.0512 |
| Cost of Revenue, Total | 1.59957 | 4.04647 | 7.42711 | 2.41583 |
| Gross Profit | 6.21169 | 5.513 | 8.15006 | 11.6354 |
| Total Operating Expense | 25.8593 | 26.8415 | 34.8894 | 39.6899 |
| Selling/General/Admin. Expenses, Total | 15.5932 | 15.675 | 19.7272 | 11.2618 |
| Depreciation / Amortization | 6.87799 | 6.66044 | 5.29111 | 8.06499 |
| Unusual Expense (Income) | 0 | 2.44393 | 17.9473 | |
| Operating Income | -18.048 | -17.282 | -19.3122 | -25.6387 |
| Interest Income (Expense), Net Non-Operating | 9.06134 | -4.73088 | -13.845 | -11.8568 |
| Other, Net | 0 | 5.00947 | ||
| Net Income Before Taxes | -8.98668 | -22.0129 | -33.1572 | -32.4861 |
| Net Income After Taxes | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Net Income Before Extra. Items | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Net Income | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Income Available to Common Excl. Extra. Items | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Income Available to Common Incl. Extra. Items | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Diluted Net Income | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Diluted Weighted Average Shares | 10.8898 | 9.70766 | 9.70774 | 9.70774 |
| Diluted EPS Excluding Extraordinary Items | -0.82524 | -2.12059 | -3.34901 | -3.34503 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.82524 | -2.12059 | -3.18537 | -2.14334 |
| Research & Development | 1.78849 | 0.45964 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 2.46517 | 7.81126 | 2.14517 | 2.45765 | 4.07561 |
| Revenue | 2.46517 | 7.81126 | 2.14517 | 2.45765 | 4.07561 |
| Cost of Revenue, Total | 0.47234 | 1.59957 | 0.31916 | 0.39329 | 0.64339 |
| Gross Profit | 1.99283 | 6.21169 | 1.82601 | 2.06436 | 3.43222 |
| Total Operating Expense | 2.94637 | 25.8593 | 5.74179 | 6.73834 | 6.27311 |
| Selling/General/Admin. Expenses, Total | 3.89774 | 15.5932 | 3.41322 | 4.11617 | 3.88172 |
| Research & Development | 0.40536 | 1.78849 | 0.28058 | 0.50005 | 0.01918 |
| Depreciation / Amortization | 1.56087 | 6.87799 | 1.72883 | 1.72883 | 1.72883 |
| Operating Income | -0.4812 | -18.048 | -3.59662 | -4.28069 | -2.1975 |
| Interest Income (Expense), Net Non-Operating | 0.30697 | 9.06134 | 1.90206 | 2.17447 | 5.20659 |
| Net Income Before Taxes | -0.17422 | -8.98668 | -1.69455 | -2.10622 | 3.00908 |
| Net Income After Taxes | -0.17422 | -8.98668 | -1.6969 | -2.11292 | 3.00908 |
| Net Income Before Extra. Items | -0.17422 | -8.98668 | -1.6969 | -2.11292 | 3.00908 |
| Net Income | -0.17422 | -8.98668 | -1.6969 | -2.11292 | 3.00908 |
| Income Available to Common Excl. Extra. Items | -0.17422 | -8.98668 | -1.6969 | -2.11292 | 3.00908 |
| Income Available to Common Incl. Extra. Items | -0.17422 | -8.98668 | -1.6969 | -2.11292 | 3.00908 |
| Diluted Net Income | -0.17422 | -8.98668 | -1.6969 | -2.11292 | 3.00908 |
| Diluted Weighted Average Shares | 20.6847 | 10.8898 | 9.8266 | 9.80231 | 9.75469 |
| Diluted EPS Excluding Extraordinary Items | -0.00842 | -0.82524 | -0.17268 | -0.21555 | 0.30848 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.17231 | -0.82524 | -0.17268 | -0.21555 | 0.30848 |
| Unusual Expense (Income) | -3.38994 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 30.5427 | 25.9051 | 12.0875 | 15.808 |
| Cash and Short Term Investments | 23.8476 | 17.1443 | 2.14814 | 4.20121 |
| Cash | 23.8476 | 17.1397 | 2.14581 | 2.79413 |
| Short Term Investments | 0 | 0.00458 | 0.00233 | 1.40708 |
| Total Receivables, Net | 2.45539 | 5.15297 | 2.60513 | 3.51207 |
| Accounts Receivable - Trade, Net | 2.45539 | 5.15297 | 2.60513 | 3.51207 |
| Total Inventory | 0.51965 | 0.76053 | 2.20443 | 6.49024 |
| Prepaid Expenses | 1.58132 | 1.42796 | 3.19392 | 1.46502 |
| Other Current Assets, Total | 2.13876 | 1.41933 | 1.9359 | 0.13947 |
| Total Assets | 67.3901 | 69.854 | 58.3663 | 66.8861 |
| Property/Plant/Equipment, Total - Net | 0.52495 | 0.64379 | 0.74208 | 0 |
| Goodwill, Net | 0 | 2.44393 | ||
| Intangibles, Net | 25.2931 | 32.1609 | 38.8111 | 44.1005 |
| Other Long Term Assets, Total | 11.0293 | 11.1443 | 6.72556 | 4.53364 |
| Total Current Liabilities | 30.9801 | 41.894 | 41.1043 | 38.5409 |
| Accounts Payable | 4.55797 | 5.60956 | 3.77644 | 1.7522 |
| Accrued Expenses | 23.5402 | 26.7291 | 23.6406 | 17.076 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 7.17503 | 6.68194 | 19.341 |
| Other Current Liabilities, Total | 2.88194 | 2.38032 | 7.00536 | 0.37166 |
| Total Liabilities | 31.8451 | 52.385 | 50.3471 | 68.5674 |
| Total Long Term Debt | 0 | 0 | 7.06103 | 27.8911 |
| Long Term Debt | 0 | 7.06103 | 27.8911 | |
| Deferred Income Tax | 1.43217 | 2.07803 | ||
| Other Liabilities, Total | 0.86502 | 10.4909 | 0.74955 | 0.0574 |
| Total Equity | 35.545 | 17.469 | 8.01922 | -1.68127 |
| Preferred Stock - Non Redeemable, Net | 0 | 20.0182 | 0 | |
| Common Stock | 0.00207 | 0.00097 | 29.1172 | 0 |
| Retained Earnings (Accumulated Deficit) | -70.6888 | -61.7021 | -41.1162 | -1.68127 |
| Total Liabilities & Shareholders’ Equity | 67.3901 | 69.854 | 58.3663 | 66.8861 |
| Total Common Shares Outstanding | 20.6847 | 9.70766 | 9.70774 | 9.70774 |
| Additional Paid-In Capital | 106.232 | 79.1702 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 26.8381 | 30.5427 | 13.3543 | 16.2341 | 23.9637 |
| Cash and Short Term Investments | 17.6719 | 23.8476 | 8.13518 | 11.0312 | 14.5713 |
| Cash | 17.6719 | 23.8476 | 8.13518 | 11.0312 | 14.5667 |
| Short Term Investments | 0 | 0 | 0 | 0.00458 | |
| Total Receivables, Net | 3.74078 | 2.45539 | 1.95242 | 2.02092 | 6.1942 |
| Accounts Receivable - Trade, Net | 3.74078 | 2.45539 | 1.95242 | 2.02092 | 6.1942 |
| Total Inventory | 1.94287 | 0.51965 | 0.51848 | 0.43923 | 0.56086 |
| Prepaid Expenses | 1.37845 | 1.58132 | 0.83102 | 1.30183 | 1.23569 |
| Other Current Assets, Total | 2.10414 | 2.13876 | 1.91721 | 1.4409 | 1.40162 |
| Total Assets | 55.8642 | 67.3901 | 52.0353 | 56.6702 | 66.154 |
| Property/Plant/Equipment, Total - Net | 0.49444 | 0.52495 | 0.55465 | 0.58356 | 0.61144 |
| Intangibles, Net | 23.7348 | 25.2931 | 26.9821 | 28.7084 | 30.4347 |
| Other Long Term Assets, Total | 4.79677 | 11.0293 | 11.1443 | 11.1443 | 11.1443 |
| Total Current Liabilities | 10.2887 | 30.9801 | 33.5006 | 34.4899 | 40.2204 |
| Accounts Payable | 3.70033 | 4.55797 | 5.31234 | 2.59789 | 5.27628 |
| Accrued Expenses | 5.29205 | 23.5402 | 21.3846 | 25.2862 | 26.8111 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.72398 | 0 | 1.74075 | 3.42538 | 5.06126 |
| Other Current Liabilities, Total | 0.57239 | 2.88194 | 5.06293 | 3.1805 | 3.07176 |
| Total Liabilities | 20.1376 | 31.8451 | 34.1883 | 37.1795 | 45.2309 |
| Total Long Term Debt | 9.47778 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.37105 | 0.86502 | 0.68775 | 2.68957 | 5.01051 |
| Total Equity | 35.7266 | 35.545 | 17.847 | 19.4907 | 20.9231 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00207 | 0.00207 | 0.00098 | 0.00098 | 0.00098 |
| Additional Paid-In Capital | 106.588 | 106.232 | 80.3489 | 80.2957 | 79.6152 |
| Retained Earnings (Accumulated Deficit) | -70.863 | -70.6888 | -62.5029 | -60.806 | -58.6931 |
| Total Liabilities & Shareholders’ Equity | 55.8642 | 67.3901 | 52.0353 | 56.6702 | 66.154 |
| Total Common Shares Outstanding | 20.6847 | 20.6847 | 9.8266 | 9.8266 | 9.79826 |
| Long Term Debt | 9.47778 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -8.98668 | -20.5859 | -32.5113 | -32.4727 |
| Cash From Operating Activities | -11.862 | -15.3053 | 2.53248 | 8.02077 |
| Amortization | 6.65022 | 5.2894 | 8.06499 | |
| Deferred Taxes | 0 | -1.43217 | -0.64587 | -0.00694 |
| Non-Cash Items | -8.05974 | 5.65288 | 17.3305 | 27.5022 |
| Cash Interest Paid | 0.42182 | 1.1914 | 2.04097 | 2.73842 |
| Changes in Working Capital | -1.69361 | -5.60055 | 13.068 | 4.93318 |
| Cash From Investing Activities | 0 | -0.00463 | -0.07154 | -1.87566 |
| Capital Expenditures | 0 | -0.00463 | -0.07154 | -1.87566 |
| Cash From Financing Activities | 18.5699 | 30.3038 | -3.10925 | -2.54776 |
| Issuance (Retirement) of Stock, Net | 25.7574 | 0.02055 | 2.90401 | 0 |
| Issuance (Retirement) of Debt, Net | -7.18753 | 8.78391 | -6.01326 | -2.54776 |
| Net Change in Cash | 6.70788 | 14.9939 | -0.64831 | 3.59734 |
| Cash From Operating Activities | 6.87799 | 0.01022 | 0.0017 | |
| Financing Cash Flow Items | 0 | 21.4994 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -0.17422 | -8.98668 | -0.80073 | 0.89616 | 3.00908 |
| Cash From Operating Activities | -5.2757 | -11.862 | -3.55773 | -2.34637 | -0.44658 |
| Cash From Operating Activities | 1.56087 | 6.87799 | 5.18649 | 3.45766 | 1.72883 |
| Deferred Taxes | 0 | 0 | 0 | 0 | |
| Non-Cash Items | -3.57792 | -8.05974 | -8.38788 | -6.82428 | -4.84613 |
| Cash Interest Paid | 0 | 0.42182 | 0.39358 | 0.3095 | 0.17668 |
| Changes in Working Capital | -3.08443 | -1.69361 | 0.44439 | 0.1241 | -0.33837 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | |
| Capital Expenditures | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | -0.9 | 18.5699 | -5.44678 | -3.76215 | -2.1264 |
| Issuance (Retirement) of Debt, Net | -0.9 | -7.18753 | -5.44678 | -3.76215 | -2.1264 |
| Net Change in Cash | -6.1757 | 6.70788 | -9.00451 | -6.10852 | -2.57298 |
| Financing Cash Flow Items | 0 | 0 | 0 | ||
| Issuance (Retirement) of Stock, Net | 25.7574 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Petros Pharmaceuticals, Inc. Company profile
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Petros Pharmaceuticals Inc revenues totaled $8.7M. Net loss totaled to $801K.
| Industry: | Biotechnology & Medical Research (NEC) |
1185 Avenue Of The Americas, 3Rd Floor
Suite 570
10036
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com